Clinical trial
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
NCT00295503 · University of Texas Southwestern Medical Center, Other · Completed
Key facts
| NCT number | NCT00295503 |
|---|---|
| Title | Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma |
| Official title | A Phase II Trial of Cisplatin, Pemetrexed and Bevacizumab in Untreated Malignant Mesothelioma |
| Lead sponsor | University of Texas Southwestern Medical Center, Other |
| Collaborators | University of Chicago Columbia University Duke University |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mesothelioma |
| Intervention type | Drug |
| Interventions | bevacizumab, cisplatin, pemetrexed |
| Enrollment | 53 |
| Start date | Feb 1, 2006 |
| Primary completion | Jun 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Feb 23, 2006 |
| Last update posted | Oct 20, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: